Carl Zeiss Meditec AG Financial Results H1 2024/25 | Order Intake Momentum

Carl Zeiss Meditec AG H1 2024/25: Key TakeawaysCarl Zeiss Meditec AG H1 FY 2024/25: Innovation-Driven Growth in Precision MedicinePresented by Sebastian Frericks, Head of Investor RelationsIn this clear and concise investor update, Sebastian Frericks, Head of Investor Relations at Carl Zeiss Meditec AG, presents the half-year results for fiscal year 2024/25, providing investors with a focused view on performance drivers, segment dynamics, and the outlook for the second half.Strong Revenue Growth Across Core SegmentsCarl Zeiss Meditec reported a strong performance in the first six months, with revenue increasing by 8.1% to €1.57 billion, compared to €1.45 billion in the prior-year period. This growth was largely driven by continued global demand in ophthalmology, alongside solid momentum in surgical visualisation solutions.Ophthalmic Devices as a Growth EngineThe Ophthalmic Devices segment remained the strongest growth engine, benefiting from strong demand for refractive lasers, intraocular lenses, and diagnostic systems. Strategic investments in innovation and sales infrastructure continue to pay off, supporting volume and value expansion.Microsurgery Segment ExpansionThe Microsurgery segment also performed well, with increased demand for digital visualisation systems used in neurosurgery and ENT procedures. Revenue from this unit grew across all core regions, including EMEA, the Americas, and Asia-Pacific.Profitability and Investment FocusFrom a profitability standpoint, the EBIT margin before special items was 17.5%, slightly lower than the 18.5% recorded in the prior year. This was primarily due to increased R&D investments and higher personnel costs linked to expansion initiatives. Nonetheless, the company reaffirmed its mid-term EBIT margin target of 20%, underlining its long-term focus on scalable and innovation-led growth.Key Highlights from H1Other highlights from Sebastian Frericks include:Solid growth across both product segments and key regionsContinued investments in R&D and digital transformationIncreased service revenue and consumables are driving margin stabilityPositive customer sentiment and strong order intake heading into H2Full-Year 2024/25 Guidance ReaffirmedImportantly, Carl Zeiss Meditec reaffirmed its full-year guidance, expecting:Revenue growth in the high single-digit rangeA stable EBIT margin before special items between 17% and 20%Accelerated innovation output in diagnostics, robotics, and AI-driven solutionsConclusion: Positioned for Sustainable GrowthThis presentation offers valuable insights into how Zeiss not only navigates a complex market but also thrives, maintaining strong fundamentals, expanding global reach, and executing its innovation strategy with resilience and adaptability.With its balanced portfolio, robust cash position, and leadership in precision medicine, Carl Zeiss Meditec remains well-positioned to deliver sustainable growth in the evolving healthcare technology landscape.▶️ Other videos: Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/ Company Presentation: https://seat11a.com/investor-relations-company-presentation/ Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/ Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ ESG Presentation: https://seat11a.com/investor-relations-esg/ 📲 Follow seat11a:🔗 Website: https://seat11a.com📢 LinkedIn: https://www.linkedin.com/company/seat11a🐦 Twitter: https://x.com/seat11a_com🎧 Spotify: https://open.spotify.com/show/1XXbzcQmY3fbeeoodYIO0HT&C This publication is intended solely for informational purposes and does not constitute investment advice. By using this website, you agree to our terms and conditions as outlined on www.seat11a.com/legal and www.seat11a.com/imprint.